Introduction
Attachment of fluorine atoms on the sugar and heterocyclic moieties of nucleoside analogues can impart potent anticancer and antiviral activity [1, 2] . The small size and powerful electronegativity of fluorine can cause significant effects on the metabolic pathway as compared to the natural nucleoside analogues. The best known examples are 5-fluorouracil (inhibitor of thymidylate synthase) [3], 2 0 -deoxy-2 0 -(fluoromethylene)cytidine [4] and 2 0 -deoxy-2 0 -difluorocytidine [5] [gemcitabine, inhibitors of ribonucleotide diphosphate reductase (RDPR)], and 4 0 ,5 0 -unsaturated 5 0 -fluoroadenosine (inhibitor of the adenosylhomocysteine hydrolase) [6] among others [1, 2] . and Czernecki et al. [7b] prepared 2 0 -deoxy-2 0 -spirocyclopropane nucleosides (e.g., A) as putative inhibitors of the RDPR (Fig. 1) . Other fused-and spiro-cycloalkyl derivatives of naturally occurring carbohydrate and nucleoside analogues with restrictions in their conformational flexibility were also designed and synthesized [7] [8] [9] [10] [11] . Marquez and coworkers elegantly demonstrated that bicyclo[3. 1.0] hexane scaffold of carbocyclic nucleosides can be used to differentiate the contrasting conformational preferences between kinases and polymerases [12] .
It is well known that geminal fluorine substituents on cyclopropane give rise to a substantial increase in ring strain which leads to an increasing ease of cleavage [13] . The kinetic effect of the 9-10 kcal/mol of incremental strain is derived largely from a homolytic cleavage of the carbon-carbon bond which is opposite to the CF 2 group. We designed gem-difluoro substituted 2 0 -deoxyuridine 2 0 -spirocyclopropane B as a potential inhibitor of RDPR since the abstraction of H3 0 by the radical initiator (Cys439) from C3 0 of the 5 0 -diphosphate C and distal (to the fluorine substituents) ring opening of the spiro 2,2-difluorocyclopropylcarbinyl radical D would result in generation of the corresponding 2,2-difluoro-3-butenyl radical species E which might cause inactivation of RDPR. The calculated activation barrier of 1.9 kcal/mol and an estimated ring opening rate constant of 1.5 Â 10 11 s À1 at 25 8C qualifies the difluorocyclopropylcarbinyl system [13b] as a ''hypersensitive'' probe of reactions involving radicals as intermediates.
Recently, Nowak and Robins reported meticulous studies on the addition of difluorocarbene [generated from either Hg(CF 3 ) 2 or PhHgCF 3 and NaI] to double bonds placed between carbons 3 0 -4 0 and 4 0 -5 0 in the ribose rings of nucleosides (all electron rich vinyl ethers) to give derivatives with the 3 0 ,4 0 -fused and 4 0 -spiro difluorocyclopropane rings, respectively [11] . We now report studies on the reactions of difluorocarbene, generated from the Difluorocarbene, generated from trimethylsilyl fluorosulfonyldifluoroacetate (TFDA), reacts with the uridine and adenosine substrates preferentially at the enolizable amide moiety of the uracil ring and the 6-amino group of the purine ring. 2 0 ,3 0 -Di-O-benzoyl-3 0 -deoxy-3 0 -methyleneuridine reacts with TFDA to produce 4-O-difluoromethyl product derived from an insertion of difluorocarbene into the 4-hydroxyl group of the enolizable uracil ring. Reaction of the difluorocarbene with the adenosine substrates having the unprotected 6-amino group in the purine ring produced the 6-N-difluoromethyl derivative, while reaction with 6-N-benzoyl protected adenosine analogues gave the difluoromethyl ether product derived from the insertion of difluorocarbene into the enol form of the 6-benzamido group. Treatment of the 6-N-phthaloyl protected adenosine analogues with TFDA resulted in the unexpected one-pot conversion of the imidazole ring of the purine into the corresponding N-difluoromethylthiourea derivatives. Treatment of the suitably protected pyrimidine and purine nucleosides bearing an exomethylene group at carbons 2 0 , 3 0 or 4 0 of the sugar rings with TFDA afforded the corresponding spirodifluorocyclopropyl analogues but in low yields.
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trimethylsilyl fluorosulfonyl-difluoroacetate (TFDA) [14] , with the purine and pyrimidine nucleosides bearing a less reactive exomethylene double bond on the ribose ring. The TFDA reagent was selected because of (a) its lower toxicity as compared to the Hg-based reagents, (b) its capability of generating difluorocarbene at a lower temperature than is usually required for most reagents, and (c) the fact that all the products of the fluoride-catalyzed thermal decomposition of TFDA, other than :CF 2 and the recycled fluoride, are gases which are lost from the reaction mixture.
Results and discussion
We chose diacetone 3-deoxy-3-methyleneglucose [15] 1 as a convenient substrate to study the feasibility of the addition of difluorocarbene to exomethylene double bonds of pentofuranose sugar rings that are not electron rich vinyl ethers. Treatment of 1 with difluorocarbene generated in situ from ''acid free'' trimethylsilyl fluorosulfonyldifluoroacetate (TFDA) [14] produced spirodifluorocyclopropane derivatives 2a and 2b (20%, 2:1; Scheme 1). (d 3.80), whereas a weak correlation was noted between H3 0 and H4 for 2b(3S). The difluorocarbene appears to have added preferentially to the more hindered a-face to give 2a as the major isomer. This is in contrast to the stereoselective b-face reduction that is observed for the NaBH 4 reduction of the 3-keto and 3-deoxy-3-methylene derivatives of diacetoneglucose [16] .
The attempted difluorocyclopropanation reaction of closely related nucleoside analogue 3 0 -deoxy-3 0 -methyleneuridine 4a produced instead 4-O-difluoromethyl product 5 (68%), derived from an insertion of difluorocarbene into the 4-hydroxyl group of the enolizable uracil ring (Scheme 2). The pair of doublet of In addition to 5, a sugar byproduct whose structure was assigned as ribosyl fluoride [17] 6 (8%) was also isolated. A similar insertion of difluorocarbene, generated from Seyferth's phenyl(trifluoromethyl) mercury reagent, into the 4-hydroxyl group of a uracil ring has been observed [18] . When the reaction between 4a and TFDA was carried out in toluene (110 8C) the ratio of products changed [5 (30%) and 6 (23%)].
In an attempt to prevent difluorocarbene insertion into the 4-hydroxyl of the uracil ring the substrates 4b and 7b with unenolizable uracil rings protected with benzoyl and methyl groups at N3 were prepared. Unfortunately, treatment of 4b with TFDA resulted mainly in removal of the N-benzoyl group from the uracil aglycone giving 4a (70%) plus 5 (13%).
Difluorocyclopropanation of 3-N-2 0 ,5 0 -O-trimethylated derivative 7b did lead to formation in a low yield of the desired 3 0 -spirodifluorocyclopropyl uridine analogues 8a and 8b [10%, Based on the known greater reactivity of the 2 0 -deoxy-2 0 -methylene nucleosides than the corresponding 3 0 -methylene counterparts in 1,3-dipolar cycloaddition reactions with diazomethane [7c], we turned our attention to difluorocyclopropantion of the 2 0 -deoxy-2 0 -methyleneuridine derivatives. Unfortunately, reaction of the trimethylated 9c with TFDA in benzene failed to give the corresponding 2 0 -spirodifluorocyclopropyl products. Use of higher temperatures (toluene) and extended reaction times (14 h) led to hydrolysis of the glycosylic bond and insertion of difluorocarbene at 2 position of the pyrimidine base to give 2-O-difluoromethyl-3-N-methyluracil 10 (17%) in addition to 11 (11%; Scheme 4). Traces of acid present in the TFDA reagent and the high temperature of these reactions presumably cause glycosylic bond cleavage, particularly for the less stable 2 0 -deoxy substrates.
The 5,6-double bond of the uracil ring of 7b or 9c was also unreactive to difluorocyclopropanation under these conditions, with no products containing a difluoro[4.1.0]bicyclic ring being observed. Additions of (di)halocarbenes generated from the corresponding di(or tri)haloacetic acid or acetates to uracil ring are known [19] , although no example of such a difluorocarbene addition has been reported. It is also worth mentioning that an attempted cyclopropanation of the 3-N-benzoyl-3 [20] with diazomethane, followed by the photochemical extrusion of nitrogen as demonstrated by and Czernecki et al. [7b] for the synthesis of unfluorinated spirocyclopropyl derivatives, also failed to give the desired spirodifluorocyclopropyl analogues.
We also performed reactions of purine nucleosides with TFDA. To test the interaction of difluorocarbene with the unprotected exo amino group in the purine ring, we carried out reactions with 5
Thus, treatment of 12 with TFDA in toluene led to the formation of 6-N-difluoromethyl derivative 13 (18%) and 6-N-formyladenosine analogue 14 (33%, Scheme 5). Although we did not investigate this reaction in details, based on the NMR and TLC analysis of the aliquots taken during the reaction, it appears that 13 is formed initially and then is slowly converted to 14.
Treatment of the adenosine analogue 15b with the exo amino group of the adenine ring protected with diethyl groups [21a] Moreover, the UV spectrum of 16 (l max 276 nm) is identical to those of 15a (l max 277 nm) and 6-N,N-dimethylamino-9-methyladenine (l max 276 nm) while a bathochromic shift was observed for the 6-N,N-dimethylamino-7-methyladenine regioisomer (l max 291 nm) [21c] .
Next, reactions of highly electrophilic difluorocarbene with nucleosides containing an electron rich vinyl ether unit were examined. However, treatment of 2 0 ,3 0 -di-O-acetyl-6-N-benzoyl protected 18b with TFDA produced the difluoromethyl ether 19 (68%), as a result of the insertion of difluorocarbene into the enol form of the 6-benzamido group, together with two minor byproducts containing fluorine ($10%, 1 H and 19 F NMR) which also had intact exomethylene units present (Scheme 7).
In order to eliminate the interaction of the difluorocarbene with the 6-N-benzoyl protecting group, we tested 6-N-phthaloyl protection [22] for the exo amino group in the adenine ring, since a phthaloyl strategy for the protection of an amino group had previously been used for the reaction with TFDA [14] . Thus, treatment of 20b [prepared (76%) by reaction of 9-(2,3-Oisopropylidene-5-deoxy-b-D-erythro-pent-4-enofuranosyl) adenine [23] 20a with phthaloyl dichloride in pyridine] with TFDA followed by column chromatography afforded 21a and 21b in 11% and 6% yield, respectively (Scheme 8). The 19 F NMR spectrum for each product showed two sets of signals, one from the spirodifluorocyclopropane ring and the second from a CF 2 H unit. Slightly different 1 H NMR spectra for both products 21a and 21b showed only singlets for purine H2 proton and a characteristic triplet (J = 58 Hz) for the CF 2 H groups. On the basis of the overall spectroscopic evidence and studies of the reaction of TFDA with model imidazole compounds, including an X-ray structure determination, a thiourea entity bearing a difluoromethyl group attached to N7 was proposed as the structure of 21a [24] . A structure for the second product was tentatively assigned as 21b based on: (i) the UV spectrum of 21b (l max 278 nm) did not exhibit bathochromic shifts as observed for thione 21a (l max 319 nm); and (ii) NOESY experiment showed correlations between H5 0 and H3 0 confirming the a-face addition of difluorocarbene to exomethylene double bond while such correlation was not observed for 21a.
The formation of the N-difluoromethylthiourea-type product 23 (18%) was also observed in the reaction of the protected adenosine derivative 22b with TFDA, although the 1-fluoro sugar byproduct 17 (32%) was a major product isolated from the reaction mixture (Scheme 9).
We also attempted difluorocyclopropanation of a ribose derivative having an exomethylene group at C2 next to the anomeric carbon. Thus, treatment of methyl-3,5-di-O-(4-chlorobenzyl)-2-deoxy-2-methylene-a-D-ribofuranoside 24 [25] with TFDA afforded methyl furanoside 25a(2R) and furanose 25b(2S) with a free hydroxyl group at C1 (35%, 7:1; Scheme 10). A NOESY experiment with 25a showed a correlation between one of the protons from the cyclopropyl ring (H2 0 ) and H1 and H3, while no such correlation was observed with 25b confirming a-face and bface addition of difluorocarbene.
Conclusions
In summary, we have shown that difluorocarbene, generated from trimethylsilyl fluorosulfonyldifluoroacetate (TFDA), reacts with the uridine substrates to produce 4-O-difluoromethyl products derived from the insertion of difluorocarbene into the 4-hydroxyl group of the enolizable uracil ring. Similar reactions of difluorocarbene with adenosine substrates having unprotected 6-amino group of the purine ring produced a 6-N-difluoromethyl derivative, while reaction with 6-N-benzoyl protected substrates gave difluoromethyl ether products derived from the insertion of difluorocarbene into the enol form of the 6-benzamido group. Treatment of the 6-N-phthaloyl protected adenosine analogues with TFDA resulted in one-pot conversion of the imidazole ring of the purine into the corresponding N-difluoromethylthiourea derivatives. Treatment of suitably protected carbohydrates as well as pyrimidine and purine nucleosides bearing an exomethylene group at carbons 2 0 , 3 0 or 4 0 of the sugar rings with TFDA gave the corresponding spirodifluorocyclopropyl analogues, but in low yields. (230-400 mesh) was used for column chromatography. An ''acid free'' trimethylsilyl 2-fluorosulfonyl-2,2-difluoroacetate (TFDA) was prepared by treatment of the equimolar quantity of TFDA with triethylamine as reported [14] . The purity of TFDA was conveniently evaluated by 19 F NMR in CDCl 3 (dried over molecular sieves 4 Å ) where TFDA shows peak at d À103.20 while the signal from 2-fluorosulfonyl-2,2-difluoroacetic acid (FDA) appears at d À103.91. TFDA and FDA were purchased from Aldrich Co. Sodium fluoride (NaF) was dried in the oven. Reactions with TFDA were carried out in 10 or 25 mL three-necked flasks equipped with a magnetic stirrer, a funnel with nitrogen (N 2 ) inlet and a watercooled condenser with gas outlet. Carbohydrates and nucleosides substrates have to be well dried prior to use. [15] (150 mg, 0.58 mmol) in anhydrous benzene (1.5 mL) containing dried NaF (1.4 mg, 0.03 mmol) was heated at 80 8C (oil bath) for 30 min. An ''acid free'' trimethylsilyl fluorosulfonyldifluoroacetate [14] (TFDA; 0.30 mL, 380 mg, 1.5 mmol) was then added dropwise via a Teflon needle at the rate of 0.15 mL/h (controlled by syringe pump). The solution was refluxed for 3 h and then cooled to ambient temperature and was evaporated to give crude mixture of 2a/2b ($20% 1.84 (ddd, J = 4.6, 8.1, 12.0 Hz, 1H), 3.80 (ddd, J = 4.8, 6.3, 7. 
Experimental section
A solution of 4a (65 mg, 0.14 mmol) in anhydrous benzene (1.5 mL) containing NaF (1.4 mg, 0.03 mmol) was heated at 80 8C (oil bath) for 30 min. TFDA (0.25 mL, 320 mg, 1.28 mmol) was added dropwise via a Teflon needle at the rate of 0.15 mL/h (controlled by syringe pump). The solution was refluxed for 3 h and then was cooled to ambient temperature. The reaction mixture was partitioned (NaHCO 3 /H 2 O//CHCl 3 ) and the separated organic layer was washed (brine), dried (Na 2 SO 4 ), evaporated and column chromatographed (20 ! 40% EtOAc/hexane) to give 5 (49 mg, 68%) as an oil: 129.3, 129.7, 129.9, 130.3, 133.9, 134.0, 141.5, 145.6, 154.4, 166.0, 166.5, 168 .1 (t, J = 3.9 Hz); HRMS calcd for C 25 Treatment of 4a (65 mg, 0.14 mmol) with TFDA (0.25 mL, 320 mg, 1.28 mmol) in toluene [1.5 mL; 110 8C (oil bath)/3 h] instead of benzene gave 5 (22 mg, 30%) and 6 (12 mg, 23%).
Analogous treatment of 4b (150 mg, 0.27 mmol) with TFDA (toluene, 3 h) gave 5 (18 mg, 13%), 4a (85 mg, 70%) and unchanged 4b (10 mg, 7%).
Step a. An ethereal solution of the excess diazomethane [generated from (N-methyl-N-nitroso)-p-toluenesulfonamide (DIAZALD; 0.55 g, 2.6 mmol)] was added to a stirred solution of 3 0 -deoxy-3 0 -methyleneuridine [26] (3; 184 mg, 0.77 mmol) in EtOH (2 mL). After 1 h, the volatiles were evaporated to give 3 0 -deoxy-3-N-methyl-3 0 -methyleneuridine (7a; 195 mg, 100%) which was directly used in next step: 27.6, 56.8, 59.4, 73.0, 79.9, 85.7, 88.7, 101.7, 112.3, 138.1, 142.9, 151.1, 162.8 8a/8b) . A solution of 7b (70 mg, 0.25 mmol) in anhydrous toluene (1.0 mL) containing NaF (1.4 mg, 0.03 mmol) was refluxed for 15 min. TFDA (0.10 mL, 127 mg, 0.51 mmol) was then added dropwise via a Teflon needle at the rate of 0.15 mL/h (controlled by syringe pump). The solution was refluxed for 6 h and then was cooled to ambient temperature and was evaporated to give mainly unchanged substrate 7b in addition to two minor less polar products 8a and 8b (TLC, 19 F NMR). The reaction mixture was partitioned (NaHCO 3 /H 2 O//CHCl 3 ) and the separated organic layer was washed (brine), dried (Na 2 SO 4 ), evaporated and column chromatographed (20 ! 50% EtOAc/hexane) to give in order of elution 8a(3 0 R) (2 mg, 2.5%), 8b(3 0 S) (2 mg, 2.5%) and 7b (29 mg, 41%) as slightly yellow oils. Compound 8a had: 1 H NMR d 1.34 (ddd, J = 4.6, 8.4, 13. 
Step a. An ethereal solution of the excess of diazomethane [generated as described for 7b (step a)] was added to a stirred solution of 2 0 -deoxy-2 0 -methyleneuridine [26] (9a; 411 mg, 1.71 mmol) in EtOH (5 mL). After 1 h, the volatiles were evaporated to give 2 0 -deoxy-3-N-methyl-2 0 -methyleneuridine (9b; 435 mg, 100%) which was directly used in next step: Step b. NaH (356 mg, 8.9 mmol, 60% dispersion in oil) and dimethyl sulfate (0.42 mL, 564 mg, 4.47 mmol) was added to a stirred solution of 9b (435 mg, 1.71 mmol) in THF (5 mL) at ambient temperature. After 14 h, glacial AcOH was added to neutralize reaction mixture to pH $6 and then the volatiles were evaporated. The residue was partitioned (NaHCO 3 /H 2 O//CHCl 3 ) and the organic layer was washed (brine), dried (Na 2 SO 4 ), evaporated and chromatographed (20 ! 40% EtOAc/hexane) to give 9c (383 mg, 79%) as a white solid: 27.9, 56.7, 59.4, 73.1, 81.1, 82.6, 85.5, 102.3, 114.9, 139.1, 145.1, 151.8, 162.9 ; HRMS calcd for C 13 2-O-Difluoromethyl-3-N-methyluracil (10) . A solution of 9c (70 mg, 0.25 mmol) in dry toluene (1.5 mL) containing NaF (1.4 mg, 0.03 mmol) was heated at 110 8C for 30 min. TFDA (0.10 mL, 127 mg, 0.51 mmol) was added dropwise via a Teflon needle at the rate of 0.05 mL/h (controlled by syringe pump). The resulting solution was refluxed overnight and then was cooled to ambient temperature. The reaction mixture was partitioned (NaHCO 3 /H 2 O//CHCl 3 ) and the separated organic layer was washed (brine), dried (Na 2 SO 4 ), evaporated and column chromatographed (30 ! 50% EtOAc/hexane) to give 10 [18] (7.5 mg, 17%): (14) . Treatment [toluene (1.5 mL), NaF (1.4 mg, 0.03 mmol), 120 8C (oil bath), 5.5 h] of 5 0 -O-benzoyl-2 0 ,3 0 -O-isopropylideneadenosine [27] (12; 40 mg, 0.10 mmol) with TFDA (0.25 mL, 320 mg, 1.28 mmol, adding with the rate of 0.10 mL/h), as described for 8a/8b (column chromatography: 20 ! 50% EtOAc/hexane), gave 13 (8 mg, 18%) and slightly more polar 14 (14 mg, 33%). Compound 39 (s, 3H), 1.61 (s, 3H) , 4.47 (dd, J = 4.8, 11.8 Hz, 1H), 4.61 (q, J = 3.7 Hz, 1H), 7.66 (dd, J = 3.9, 11.8 Hz, 1H), 5.06 (dd, J = 3.4, 6.3 Hz, 1H), 5.33 (dd, J = 6.3, 2.4 Hz, 1H), 5.99 (d, J = 2.4 Hz, 1H), 7.41 (t, J = 7.4 Hz, 2H), 7.56 (t, J = 7.5 Hz, 1H), 7.71 (s, 1H), 7.83 (s, 1H), 7.93 (d, J = 7.1 Hz, 2H), 7.94 (t, J = 59.9 Hz, 1H); 19 F NMR d À101.53 (dd, J = 59.7, 228.3 Hz, 1F), À102.35 (dd, J = 59.7, 228.3 Hz, 1F); 13 C NMR d 25.7, 27.5, 64.3, 81.6, 85.0, 85.1, 91.7, 107.9 (t, J = 252.8 Hz), 115.3, 124.1, 128.7, 129.6, 129.9, 133.8, 138.2, 140.1, 141.4 13 C NMR d 25.8, 27.5, 64.6, 82.0, 84.6, 85.6, 92.2, 115.2, 121.7, 128.6, 129.6, 129.8, 133.6, 143.4, 149.5, 151.4, 152.9, 163.2, 166.3 . 25.6, 27.4, 43.3 (br s), 64.8, 82.0, 84.5, 85.2, 91.6, 114.6, 120.5, 128.5, 129.6, 129.8, 133.3, 137.5, 149.9, 152.9, 153.9, 166 H, 6.25; N, 14.98. Found: C, 61.46; H, 6.62; N, . Treatment [toluene (1.5 mL), NaF (1.4 mg, 0.03 mmol), 120 8C (oil bath), 5.5 h] of 15b (55 mg, 0.12 mmol) with TFDA (0.18 mL, 229 mg, 0.91 mmol; adding at the rate of 0.10 mL/h) as described for 8a/8b (column chromatography: 20 ! 80% AcOEt/hexane) gave recovered 15b (30 mg, 55%) and 16 (6 mg, 21%) and 17 (3 mg, 9%). 1.48 (s, 3H), 4.36 (dd, J = 6.9, 11.7 Hz, 1H), 4.42 (dd, J = 5.8, 11.8 Hz, 1H), 4.68 (ddt, J = 3.1, 5.9, 6.2 Hz, 1H), 2H), 5.83 (d, J = 61.7 Hz, 1H), 7.45 (t, J = 7.9 Hz, 2H) C NMR d 25.1, 26.5, 64.8, 81.2, 85.2 (d, J = 40.6 Hz), 86.6 (d, J = 2.8 Hz), 113.4, 115.5 (d, J = 223.1 Hz), 128.7, 129.7, 130.0, 133.5, 166.3 Notes: Analogous treatment of 18b (0.15 mmol) with TFDA in toluene also gave 19 (65%). 25.9, 27.0, 79.8, 82.9, 89.6, 91.1, 114.7, 124.7, 130.2, 132.1, 135.2, 144.7, 144.9, 153.1, 153.2, 161.6, 165.7 25.6, 26.5, 73.6 (t, J = 9.3 Hz), 79.9, 85.0, 90.9, 109 .65 (t, J = 281.7 Hz), 109.69 (t, J = 255.9 Hz), 114. 2, 124.4, 124.5, 131.7, 131.8, 133.7, 134.7, 135.0, 135.1, 153.1, 154.1, 165.3,165.7, 172.1; 19 2, 123.6, 124.4, 131.8, 134.4, 134.9, 149.6, 151.3, 153.7, 165.3, 165.6 [29] (22a, 120 mg, 0.27 mmol; prepared by standard protection of 6-Nphthaloyladenosine [22] with acetone) in pyridine (3 mL) at 0 8C. After 16 h, the volatiles were evaporated and the residue was partitioned (1N HCl/H 2 O//CHCl 3 ). The organic layer was separated and was washed (NaHCO 3 /H 2 O//brine), dried (Na 2 SO 4 ), evaporated and chromatographed (30 ! 70% AcOEt/hexane) to give 22b (110 mg, 74%) as a white foam: UV (MeOH) l max 275 nm, l min 255 nm; 1 H NMR d 1.37 (s, 3H), 1.63 (s, 3H), 4.52 (dd, J = 6.6, 81.5, 83.1, 85.2, 89.8, 109.8 (t, J = 252.0 Hz), 115.5, 123.7, 124.6, 124.7, 128.6, 129.1, 130.0, 132.03, 132.05, 133.4, 134.9 (d, J = 1.4 Hz), 135.0, 135.2, 153.4, 154.2, 165.7, 166.40, 166.45, 172.0 [25] 24 (150 mg, 0.37 mmol) with TFDA [(0.3 mL, 380 mg, 1.5 mmol; added at the rate of 0.15 mL/h], as described for 2a/2b, gave 25a(2R) (51 mg, 30%) and 25b(2S) (8 mg, 5%): compound 25a: 55.3, 69.6, 71.8, 74.6, 77.1, 82.2, 102.6 (d, J = 4.8 Hz) , 111.7 (t, J = 285.0 Hz), 128.5, 128.6, 129.1, 129.2, 133.6, 133.6, 136.1, 136 1 J = 6.5, 10.7, 11.4 Hz, 1H), 1.61 (''ddd'', J = 5.7, 10.7, 11.0 Hz, 1H) C NMR d 14.5 (t, J = 10.9 Hz), 39.6 (t, J = 9.9 Hz), 68. 2, 69.3, 71.7, 72.3, 82.1, 100.7 (d, J = 4.1 Hz), 111.7 (t, J = 285.0 Hz), 128.62, 128.64, 129.0, 129.2, 129.3, 133.5, 133.6, 136.1, 136.3 
